News & Updates

Use of cardiovascular medications does not lead to poor COVID-19 clinical outcomes among high-risk patients, such as those with hypertension, according to a study.

Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

Use of 5α-reductase inhibitors (5ARIs) appears to lower the risk of community-acquired infection with SARS-CoV-2 in men without prostate cancer, according to a study, noting that treatment with this drug class can help ease the burden of COVID-19.

Several disease-modifying therapies (DMTs) for multiple sclerosis (MS) do not pose an increased risk of cancer, a study has shown.

Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.